Salmonella and Campylobacter prevalence in US retail chicken continues to decline according to the 2014 Integrated National Antimicrobial Resistance Monitoring System (NARMS) report released by the US Food and Drug Administration. Salmonella and Campylobacter prevalence in retail chicken meat samples continue to decline, and both are at their lowest levels since NARMS testing began (9.1% and 33% respectively).Most (82%) of human Salmonella isolates tested were not resistant to any of the tested antibiotics.Ceftriaxone, an extended-spectrum cephalosporin critical to treating severe Salmonella infections, continues to be effective, and resistance to the antibiotic has decreased in non-typhoidal Salmonella and E. coli.Human Salmonella isolates resistant to at least ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracyclines (ACSSuT) are at the lowest level (3.1%) since NARMS testing began.Bacterial strains that are resistant to all, or all but 1, of the 9 antimicrobial classes tested in NARMS are defined as “extremely drug resistant” by the FDA. In 2014, no retail chicken isolates of either Salmonella or E. coli were found to be extremely drug resistant.